Bottkota:

This UM (University of Miami) originated  Nab-B-G regimen (nab-paclitaxel (Abraxane) + bevacizumab (Avastin) + gemcitabine (Gemzar)) is quite well-known, having first been reported in interim form at ASCO 2006, then updated and reported by the same UM team in peer-reviewed form in 2007, and finally and most recently at ASCO 2008. I consider it an enhanced and extended version of Kathy Miller's infamous E2100 regimen (paclitaxel + bevacizumab), enhanced to substitute the superior taxane, namely nab-paclitaxel (Abraxane) instead of paclitaxel (Taxol) and extended by the addition of gemcitabine (Gemzar), known to be additive or synergistic with each of the other agents independently.  To date, it's achieved very high ORR (overall response rate) in the first-line metastatic setting, including in triple negative tumors, with 76% of patients (14) achieving partial response (PR), and 6% (1) having stable disease (SD), for an ORR of 76%, and a CBR or clinical benefit rate (CR + PR + SD) of 80% in 17 patients evaluated for efficacy.  And this Nab-B-G regimen exhibit good tolerability and safety, with no grade 3/4 adverse events; the most commonly reported side effects were alopecia (62%), fatigue (38%) and rash (23%), and note that both nab-paclitaxel (Abraxane) and gemcitabine (Gemzar) can be dose-reduced if necessary.